| Dr Patrick Elie Hallak, MD | |
|
251 E Huron St, Chicago, IL 60611-2908 | |
| (312) 926-6632 | |
| Not Available |
| Full Name | Dr Patrick Elie Hallak |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Nephrology |
| Location | 251 E Huron St, Chicago, Illinois |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770740144 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 036123751 (Illinois) | Primary |
| Entity Name | Mgmc Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891797148 PECOS PAC ID: 9537073119 Enrollment ID: O20031220000056 |
News Archive
A study by Youfa Wang, PhD, MD, assistant professor with the Centre for Human Nutrition at the Johns Hopkins Bloomberg School of Public Health, published in the current issue of the American Journal of Clinical Nutrition, has found that the size of a man's waist is a better predictor of his risk of developing type 2 diabetes than his body mass index (BMI).
Experts from the Center for Diagnostics and Telemedicine have developed a platform for self-testing services which is based on artificial intelligence and designed for medical tasks, such as for analyzing diagnostic images.
Medical University of South Carolina investigators report that long-term expansion protocols for adoptive cancer immunotherapy do not compromise Th17 cells' effectiveness against large tumors, in the March 9, 2017 issue of JCI Insight.
BD (Becton, Dickinson and Company)announced today that it signed a definitive agreement to acquire HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms. The acquisition is subject to regulatory approvals and is expected to close during the first quarter of fiscal year 2010. The financial terms of the agreement were not disclosed.
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved updated labeling for Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Patrick Elie Hallak, MD 251 E Huron St, Chicago, IL 60611-2908 Ph: (317) 837-5570 | Dr Patrick Elie Hallak, MD 251 E Huron St, Chicago, IL 60611-2908 Ph: (312) 926-6632 |
News Archive
A study by Youfa Wang, PhD, MD, assistant professor with the Centre for Human Nutrition at the Johns Hopkins Bloomberg School of Public Health, published in the current issue of the American Journal of Clinical Nutrition, has found that the size of a man's waist is a better predictor of his risk of developing type 2 diabetes than his body mass index (BMI).
Experts from the Center for Diagnostics and Telemedicine have developed a platform for self-testing services which is based on artificial intelligence and designed for medical tasks, such as for analyzing diagnostic images.
Medical University of South Carolina investigators report that long-term expansion protocols for adoptive cancer immunotherapy do not compromise Th17 cells' effectiveness against large tumors, in the March 9, 2017 issue of JCI Insight.
BD (Becton, Dickinson and Company)announced today that it signed a definitive agreement to acquire HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms. The acquisition is subject to regulatory approvals and is expected to close during the first quarter of fiscal year 2010. The financial terms of the agreement were not disclosed.
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved updated labeling for Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV.
› Verified 2 days ago
Dr. Sorin C Danciu, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3134 N Clark St, Chicago, IL 60657 Phone: 773-880-9722 | |
Anoopa A. Koshy, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 259 E Erie St Ste 2200, Chicago, IL 60611 Phone: 312-926-6000 | |
William Edmond Gerardi, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 3730 N Lake Shore Dr, Apartment 2a, Chicago, IL 60613 Phone: 773-244-3060 | |
Suparna Dutta, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1700 W Van Buren St, Suite 500, Chicago, IL 60612 Phone: 312-942-4200 Fax: 312-942-3568 | |
Alexandra Dumitrescu, Nephrology Medicare: Accepting Medicare Assignments Practice Location: 5841 S Maryland Ave, Chicago, IL 60637 Phone: 888-824-0200 | |
Dr. Mitesh Mahesh Kabadi, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St Ste 1159, Chicago, IL 60612 Phone: 312-942-5020 | |
Dr. Marta Batus, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St, Suite 809, Chicago, IL 60612 Phone: 312-563-2487 Fax: 312-942-3192 |